Objective: The exfoliative cell analyzer, LC-1000 (Sysmex Corporation, Japan), is a medical device that presents the cell proliferation index and 23 research parameters as indicators of cellular proliferative potential. The objective was to evaluate the clinical usability of qualitative assessment by LC-1000 compared with cytology, the human papillomavirus (HPV) test, and histology as gold standard. Study Design: Women that visited 3 sites between July 2015 and March 2017 were registered. The primary endpoint in this study was the comparison between LC-1000 measurement and HPV test for sensitivity and specificity for cervical intraepithelial neoplasia 2+ (CIN2+). A tree model algorithm was newly constructed by a statistical method and its relationship with histological results was evaluated. Results: The sensitivity and specificity of LC-1000 were 78.3 and 74.1%, while those of the HPV test were 94.7 and 85.4%, respectively. A tree model comprising five categories was constructed. The proportion of advanced lesions was higher with the change in the rank classification results from 1 to 5. The positive predictive values of CIN2+ in the categories 4 and 5 were high. Despite the small number of subjects, cancer was undetected in categories 1 and 2. In addition, the comparison with follow-up results in 19 women assessed as CIN1 showed that the rate of progression in the categories 3–5 was 50% (7/14); progression in the categories 1 and 2 was 0% (0/5). Conclusions: LC-1000 may be useful for cervical cancer screening as an index to qualitatively evaluate CIN and cancer based on the changes in characteristics of cells.

1.
Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan.
2.
Hamashima
C
,
Shibuya
D
,
Yamazaki
H
,
Inoue
K
,
Fukao
A
,
Saito
H
, et al
The Japanese guidelines for gastric cancer screening
.
Jpn J Clin Oncol
.
2008
Apr
;
38
(
4
):
259
67
.
[PubMed]
0368-2811
3.
OECD
.
Health at a Glance 2013: OECD Indicators
.
OECD Publishing
;
2013
.
4.
Morisaki
H
,
Abe
S
,
Ebi
R
,
Morita
M
,
Oguro
M
,
Tajima
K
, et al
A Novel Method for DNA cytometry of exfoliated cells
.
Cytometry Res
.
2014
;
24
:
41
52
.
5.
Yamasaki
T
,
Abe
S
,
Morisaki
H
,
Akamatsu
N
,
Kurusu
H
,
Ebi
R
, et al
The Flow Cytometry based cell analysis technology and Application to cervical cancer testing
.
Cytometry Res
.
2018
;
28
:
31
9
.
6.
Ebi
R
,
Tajima
K
,
Abe
S
,
Kawano
M
. Canceration information providing method and canceration information providing device. US Patent Application Publication US2013/0280729 A1,
2013
.
7.
Ebi
R
,
Tajima
K
,
Abe
S
,
Kawano
M
. Canceration information providing method and canceration information providing device. US Patent Application, Publication US2013/0280730 A1,
2013
.
8.
Ebi
R
,
Tajima
K
,
Abe
S
,
Kawano
M
.
Method for providing oncogenesis information and device for providing oncogenesis information.
European Patent Application EP2735872 A1,
2014
.
9.
Shirasuna
K
,
Ebi
R
,
Abe
S
.
Cell analysis method, cell analyzer and sample screening method
.
Eur Patent Appl
;
2015
. pp.
1
32
.
10.
Han
X
,
Ping
B
,
Morita
M
,
Ebi
R
,
Inoue
J
,
Tanaka
Y
, et al
A novel highly sensitive and specific flow cytometry system for cervical cancer screening
.
Gynecol Oncol
.
2015
Oct
;
139
(
1
):
52
8
.
[PubMed]
0090-8258
11.
Coughlin
SS
,
Trock
B
,
Criqui
MH
,
Pickle
LW
,
Browner
D
,
Tefft
MC
.
The logistic modeling of sensitivity, specificity, and predictive value of a diagnostic test
.
J Clin Epidemiol
.
1992
Jan
;
45
(
1
):
1
7
.
[PubMed]
0895-4356
12.
Smith
PJ
,
Hadgu
A
.
Sensitivity and specificity for correlated observations
.
Stat Med
.
1992
Aug
;
11
(
11
):
1503
9
.
[PubMed]
0277-6715
13.
Leisenring
W
,
Pepe
MS
,
Longton
G
.
A marginal regression modelling framework for evaluating medical diagnostic tests
.
Stat Med
.
1997
Jun
;
16
(
11
):
1263
81
.
[PubMed]
0277-6715
14.
Sternberg
MR
,
Hadgu
A
.
A GEE approach to estimating sensitivity and specificity and coverage properties of the confidence intervals
.
Stat Med
.
2001
May
;
20
(
9-10
):
1529
39
.
[PubMed]
0277-6715
15.
Pepe
MS
.
The Statistical Evaluation of Medical Tests for Classification and Prediction
.
Oxford University Press New York
;
2003
.
16.
Singh
M
,
Mehrotra
S
,
Kalra
N
,
Singh
U
,
Shukla
Y
.
Correlation of DNA ploidy with progression of cervical cancer
.
J Cancer Epidemiol
.
2008
;
2008
:
298495
.
[PubMed]
1687-8558
17.
Grote
HJ
,
Nguyen
HV
,
Leick
AG
,
Böcking
A
.
Identification of progressive cervical epithelial cell abnormalities using DNA image cytometry
.
Cancer
.
2004
Dec
;
102
(
6
):
373
9
.
[PubMed]
0008-543X
18.
Matsumoto
K
,
Oki
A
,
Furuta
R
,
Maeda
H
,
Yasugi
T
,
Takatsuka
N
, et al;
Japan HPV And Cervical Cancer Study Group
.
Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study
.
Int J Cancer
.
2011
Jun
;
128
(
12
):
2898
910
.
[PubMed]
0020-7136
19.
Cervical Cytology Practice Guidelines TOC. American Society of Cytopathology. [The guideline is available at https://www.cytopathology.org/cervical-cytology-practice-guidelines-toc/]
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.